TW200501960A - Synergistic kits and compositions for treating cancer - Google Patents

Synergistic kits and compositions for treating cancer

Info

Publication number
TW200501960A
TW200501960A TW092127035A TW92127035A TW200501960A TW 200501960 A TW200501960 A TW 200501960A TW 092127035 A TW092127035 A TW 092127035A TW 92127035 A TW92127035 A TW 92127035A TW 200501960 A TW200501960 A TW 200501960A
Authority
TW
Taiwan
Prior art keywords
synergistic
kits
compositions
treating cancer
cancer
Prior art date
Application number
TW092127035A
Other languages
English (en)
Chinese (zh)
Inventor
Joan M Carboni
Warren W Hurlburt
Marco M Gottardis
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of TW200501960A publication Critical patent/TW200501960A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW092127035A 2002-10-02 2003-09-30 Synergistic kits and compositions for treating cancer TW200501960A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41541602P 2002-10-02 2002-10-02

Publications (1)

Publication Number Publication Date
TW200501960A true TW200501960A (en) 2005-01-16

Family

ID=32069854

Family Applications (2)

Application Number Title Priority Date Filing Date
TW092127035A TW200501960A (en) 2002-10-02 2003-09-30 Synergistic kits and compositions for treating cancer
TW092127209A TW200410689A (en) 2002-10-02 2003-10-01 Synergistic methods and compositions for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW092127209A TW200410689A (en) 2002-10-02 2003-10-01 Synergistic methods and compositions for treating cancer

Country Status (7)

Country Link
US (2) US20040072760A1 (enExample)
EP (2) EP1556051A2 (enExample)
JP (2) JP2006503867A (enExample)
AU (2) AU2003282892A1 (enExample)
CA (2) CA2500714A1 (enExample)
TW (2) TW200501960A (enExample)
WO (2) WO2004030627A2 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004058821A2 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP1399484B1 (en) * 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AR046337A1 (es) * 2003-10-15 2005-12-07 Osi Pharm Inc Imidazopirazina inhibidoras de las tirosinquinasas
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
WO2005070020A2 (en) 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
JP2007523956A (ja) 2004-02-25 2007-08-23 ダナ−ファーバー キャンサー インスティテュート インク． 腫瘍細胞増殖を阻害するための方法
CN1960993A (zh) * 2004-04-02 2007-05-09 Osi制药公司 6,6－双环取代的杂双环蛋白激酶抑制剂
AU2005249492B2 (en) 2004-05-27 2011-09-22 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
EP1755608A1 (en) * 2004-06-03 2007-02-28 F.Hoffmann-La Roche Ag Treatment with gemcitabine and an egfr-inhibitor
JP2008521907A (ja) 2004-12-03 2008-06-26 シェーリング コーポレイション 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー
EP1853610A1 (en) * 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
JP5085529B2 (ja) * 2005-03-16 2012-11-28 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー 上皮成長因子受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
BRPI0611800A2 (pt) 2005-06-15 2008-12-09 Schering Corp formulaÇço estÁvel de anticorpo
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
ES2397275T3 (es) 2005-08-04 2013-03-05 Sirtris Pharmaceuticals, Inc. Derivados de imidazopiridina como agentes moduladores de la sirtuína
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8062838B2 (en) * 2005-09-20 2011-11-22 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP2004188B1 (en) * 2006-03-31 2010-09-01 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
CA2648036C (en) 2006-03-31 2012-05-22 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
DK2120932T3 (da) * 2006-12-20 2014-10-13 Nerviano Medical Sciences Srl Indazolderivater som kinasehæmmere til behandling af kræft
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
TW200900070A (en) * 2007-02-27 2009-01-01 Osi Pharm Inc Combination cancer therapy
WO2008127719A1 (en) * 2007-04-13 2008-10-23 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to kinase inhibitors
SG182170A1 (en) * 2007-06-06 2012-07-30 Domantis Ltd Polypeptides, antibody variable domains and antagonists
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
JP2011501660A (ja) * 2007-10-03 2011-01-13 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー
CA2694154A1 (en) * 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009058348A1 (en) * 2007-11-01 2009-05-07 Sirtris Pharmaceuticals, Inc. Amide derivatives as sirtuin modulators
CN101910184A (zh) * 2007-11-08 2010-12-08 西特里斯药业公司 可溶性噻唑并吡啶
US8084466B2 (en) 2007-12-18 2011-12-27 Janssen Pharmaceutica Nv Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
ES2402138T3 (es) 2007-12-28 2013-04-29 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Terapia contra el cáncer con un parvovirus combinado con quimioterapia
EP2250173A1 (en) * 2008-01-18 2010-11-17 OSI Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
RU2008106419A (ru) * 2008-02-21 2009-08-27 Закрытое акционерное общество "Ива фарм" (RU) Лекарственные средства на основе олигоядерных координационных соединений d-металлов, способ терапевтического воздействия на организм пациента и способ повышения терапевтической эффективности фармакологически активного вещества
WO2009118858A1 (ja) 2008-03-27 2009-10-01 三菱電機株式会社 エレベータの制御システム
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
CN102388054B (zh) 2008-12-19 2015-03-04 西特里斯药业公司 噻唑并吡啶沉默调节蛋白调节剂的化合物
US20110171124A1 (en) * 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
EP2421837A1 (en) 2009-04-20 2012-02-29 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US20110217309A1 (en) * 2010-03-03 2011-09-08 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
WO2012117396A1 (en) * 2011-03-01 2012-09-07 Novotyr Therapeutics Ltd Tyrphostin derivative in combination with cytotoxic compounds for treating cancer
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
ES2773543T3 (es) 2013-03-06 2020-07-13 Janssen Pharmaceutica Nv Benzoimidazol-2-ilpirimidinas moduladores del receptor de histamina H4
WO2015008206A1 (en) 2013-07-14 2015-01-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
EP3044593A4 (en) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy
KR20170109589A (ko) * 2015-02-05 2017-09-29 티르노보 리미티드 암 치료를 위한 irs/stat3 이중 조절제 및 항암제의 조합물
GB201617627D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
US10479786B2 (en) * 2016-12-13 2019-11-19 Princeton Drug Discovery, Inc Protein kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643903A1 (fr) * 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
WO2000035455A1 (en) * 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
BR0311814A (pt) * 2002-06-05 2005-03-15 Cedars Sinai Medical Center Método de tratar câncer empregando inibidores de cinase

Also Published As

Publication number Publication date
WO2004030627A2 (en) 2004-04-15
AU2003282892A1 (en) 2004-04-23
WO2004030625A3 (en) 2004-06-24
TW200410689A (en) 2004-07-01
CA2500729A1 (en) 2004-04-15
WO2004030627A3 (en) 2004-07-01
JP2006503866A (ja) 2006-02-02
JP2006503867A (ja) 2006-02-02
US20040106605A1 (en) 2004-06-03
WO2004030625A2 (en) 2004-04-15
AU2003275364A1 (en) 2004-04-23
EP1556051A2 (en) 2005-07-27
US20040072760A1 (en) 2004-04-15
EP1551411A2 (en) 2005-07-13
CA2500714A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
TW200501960A (en) Synergistic kits and compositions for treating cancer
WO2005094376A3 (en) Synergistic methods and compositions for treating cancer
ATE481092T1 (de) Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen
SG148864A1 (en) Methods of treating cancer and related methods
AU2003284242A1 (en) Methods and compositions for use in treating cancer
WO2008076278A3 (en) Methods of cancer treatment with igf1r inhibitors
TW200507833A (en) Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
AU2003291356A1 (en) Methods and compositions for treating cancer using proteasome inhibitors
WO2006015263A3 (en) Lonidamine analogs
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
BRPI0517135A (pt) composições e métodos para tratar doenças neoplásticas
WO2007053573A3 (en) Treatment of cancer with sorafenib
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
TW200508233A (en) Chk-1 inhibitors
EP1578760A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
CA3250590A1 (en) POLYTHERAPY
MXPA03002494A (es) Metodo para reducir toxicidad de quimio terapias combinadas.
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
NZ617989A (en) Use of pnp inhibitors such as forodesine in combination with alkylating agents for treating hematologic cancers
IL164356A0 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
WO2005082353A3 (en) Use of beta-lapachone for treating or preventing cancer
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
MXPA04007007A (es) Uso de inhibidores del intercambiador cloruro/bicarbonato dependiente del sodio para el tratamiento de enfermedades tromboticas e inflamatorias.